Ronald Witteles

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Jeffrey H. Schwartz, Balarama Gundapaneni, Perry Elliott et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Medicine, Cardiology, Pharmacotherapy +13

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations

Giuseppe Curigliano, Daniel J. Lenihan, Michael G. Fradley et al. · Annals of Oncology · 2020 · 1K citations · Full text

Medicine, Cardiology, Oncology +17

Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society

Alexander R. Lyon, Susan Dent, Susannah Stanway et al. · European Journal of Heart Failure · 2020 · 770 citations · Full text

Medicine, Cardiology, Oncology +16

Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity

Paul W. Burridge, Yong Fuga Li, Elena Matsa et al. · Nature Medicine · 2016 · 760 citations

Medicine, Oncology, Pharmacology +16

Genotype and Phenotype of Transthyretin Cardiac Amyloidosis

Mathew S. Maurer, Mazen Hanna, Martha Grogan et al. · Journal of the American College of Cardiology · 2016 · 534 citations · Full text

Medicine, Cardiology, Genetics +12